News

Population in Deprived Areas Have Higher Risk of Suffering Cognitive Dysfunctions

People living in regions with deprived, disadvantaged conditions have higher probabilities of suffering cognitive dysfunctions than those living in regions with more developed living conditions, according to a study from the University of Ulster in United Kingdom, led by Professor Helene McNulty. The results of the research based on Ireland data revealed…

Promising Alzheimer’s Test Enters Next Stage of Development

Amarantus BioScience Holdings, Inc. recently released promising results from the Lymphocyte Proliferation Test (LymPro Test®) blood diagnostic for Alzheimer’s disease (AD) LP-002 study. Amarantus is a biotechnology company focused on research and development of treatments and diagnostics for diseases related to neurodegenerative and apoptosis (programmed cell death) processes that contribute…

Muses Labs Brings Software Expertise to Alzheimer’s Disease Therapeutics

Muses Labs, based at Research Triangle Park in Raleigh, North Carolina, creates software-based systems to enable personalized therapy for the treatment of complex diseases. The company recently announced the development of its first offering for addressing Alzheimer’s disease. The combination therapy it implements is based on a broad understanding…

Data For New Alzheimer’s Disease Treatment For Agitation To Be Presented at Upcoming ANA Meeting

Avanir Pharmaceuticals, Inc. will present their most-recent results from two clinical trials currently underway for treating conditions associated with Alzheimer’s disease (AD). The data is set to be presented at the American Neurological Association’s (ANA) Annual Meeting in Baltimore, Maryland, from October 12-14, 2014. The phase II clinical trial evaluated…

New Financial Guidelines Posed By Industry Leaders for Advisers Working for Alzheimer’s Patients

The Massachusetts Institute of Technology (MIT) AgeLab recently joined forces with the Transamerica companies to discuss significant financial issues regarding patients suffering from Alzheimer’s and their families, as well as to initiate a framework for new guidelines in effectively serving clients facing the disease. The meeting recently took place at the “Financial…

Personalized Treatment Program May Reverse Alzheimer’s Symptoms

A novel, personalized treatment program with the ability to reverse the cognitive impairment caused by Alzheimer’s disease may have been discovered by a researcher from the Buck Institute Research on Aging, in Novato, California and the University of California-Los Angeles. The findings of the study, which focused on combined therapies…